Biogen Backs Out Of Hemophilia, But Who Benefits?
Executive Summary
With no buyers in the hemophilia space and a need to create a more streamlined company, Biogen Inc. announced May 3 that it has done the only thing it can – spin out its hemophilia business. It's still unclear whether this will be a positive strategy for either company.
You may also be interested in...
Biopharma Quarterly Dealmaking Statistics, Q2 2016
Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.
Start-Up Quarterly Statistics, Q2 2016
A review of biopharma start-up dealmaking and financing from April through June 2016, based on data from Strategic Transactions.
Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017
Bioverativ was unveiled as the name for Biogen’s spin out; an initial Form 10 registration will be filed with SEC later this week.